ICOS-Fc: Innovation & Technology

A New Immunologic Approach to treat cancer and bone-loss related diseases

NOVAiCOS ImmunoTherapeutics develops cutting-edge biotechnological solutions based on immunotherapy for the treatment of primary tumors, bone metastases and bone loss-related diseases.

At the core of our technology is ICOS-Fc, a new generation biological drug that enhances the effector and regulatory functions of various types of T cells and targets the ICOS/ICOSL immune pathway to block tumor progression, reduce osteolysis, and improve patients' quality of life.

ICOS-Fc

NOVAiCOS Innovation lies in its ability to simultaneously
address multiple aspects of the disease:

Tumor Metastasis Blockade

Inhibits tumor cell migration, reducing the spread of bone metastases.

Tumor Growth Inhibition

Prevents the formation of tumor angiogenesis, blocking the growth of cancer cells.

Restoration of Immune Balance

Enhances the immune response against tumors, increasing the effectiveness of T cells in recognizing and destroying cancer cells.

Bone Protection

Blocks bone resorption by inhibiting osteoclasts, reducing the risk of fractures.

OSTEOCLAST

TUMOR CELLS

CANCER VASCULAR CELLS

IMMUNE CELLS

Through the application of advanced nanotechnology, NOVAiCOS aims to
enhance the effectiveness of ICOS-Fc in treating primary tumors and bone
metastases, with the goal of inhibiting metastatic tumor growth and reducing
fracture incidence, ultimately improving patient survival and quality of life.

A Unique Approach

Immunotherapy and Nanotechnology

By combining molecular biology and advanced nanotechnologies, we can identify three key innovations:

The use of ICOS-Fc as a single drug for osteolysis, tumor growth, and metastases represents a significant innovation, combining both antitumor and antiosteolytic effects in a single therapy.

Identifying an optimal delivery system for ICOS-Fc targeted to tumor microenvironment is essential. The use of nanoparticles for selective drug transport represents a significant innovation.

Unlike conventional immunotherapeutics that primarily target lymphocytes, ICOS-Fc offers a multifunctional approach. It reduces immunosuppression, enhances T cell activity, modulates the tumor microenvironment, and directly inhibits tumor cell proliferation and metastasis.

NOVAiCOS approach represents a breakthrough in bone metastasis therapy,
offering a targeted and innovative treatment.

Patents

NOVAiCOS’ innovation is protected by a solid patent strategy, ensuring exclusivity and competitiveness in the field of immunotherapy for bone metastases.

NOVAiCOS holds two key patents, covering both osteoporosis therapy and cancer treatment:

NOVEL ANTI-TUMOR THERAPEUTIC AGENTS Patent status: Granted in Italy (IT) and the United States (US), pending approval in Canada (CA) and Europe (EP)

Discover more

LIGANDS OF THE B7H RECEPTOR FOR THE TREATMENT OF OSTEOPENIA AND OSTEOPOROSIS. Patent status: Granted in China (CN), Canada (CA), United States (US), and Europe (EP)